-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1st local time, gene sequencing giants Illumina and Pacific Biosciences announced an agreement to buy "rival" Pacific Biosciences for $8 a share ($1.2 billion) to strengthen its position in cutting-edge genetic research.
this is the biggest deal in Illumina's 20-year history.
the deal will bring together Illumina's short-read sequencing technology and Pacific Biosciences' long-read sequencing technology, paving the way for more perfect genome sequencing.
1, "complementary" transactions Although Illumina's precise, economical short-read sequence platform can satisfy most sequencing applications, in some areas, such as de novo sequencing and highly homologous genome region sequencing, need to be better solved through accurate long reads.
Pacific Biosciences' three-generation sequencing platform, with its unique SMRT (Molecule Single Real Time) technology, can analyze individual DNA molecules and decode long fragments of DNA with high accuracy.
"PacBio's unparalleled accuracy matches Illumina's.
combination of both, we can broaden our applications, accelerate the pace of genomic discovery, and strengthen Illumina's innovation engine. "PacBio's ongoing quest to improve sequencing accuracy while reducing costs underscores the potential for long reads to extend sequencing to new customers and applications," said Francis de Souza, President and CEO of
Illumina. Michael Hunkapiler, chief executive of
Pacific Biosciences, said: "Illumina and Pacific Biosciences share shared values and a commitment to innovation.
complement our sequencing technologies, new integrations will provide customers with new choices and open up new areas of genomic utility.
" trading volume of 71 per cent over the 30 trading days ended October 31, with a total value of about $1.2bn.
the agreement has been approved by the boards of Illumina and Pacific Biosciences.
Illumina is expected to close the deal in mid-2019.
2, the industry evaluation hand hiSeq X, Nova Seq, iSeq™100 and other star sequencing system, Illumina in the field of genetic sequencing occupies an absolute position, is the world's largest supplier of genetic testing equipment, but also the largest provider of genetic testing supplies.
Illumina has reduced the cost of sequencing individual genomes from $10 million a decade ago to less than $1,000 today, making sequencing explosive in scientific research and medical applications.
Francis de Souza hopes that Illumina will eventually be able to reduce the cost of sequencing individual genomes to $100 per person.
for the heavyweight deal, former SymeF National Clinical Market Strategy Director Chai Yingshuang believes illumina's existing technology is hardly a big breakthrough. "Long reading is an important direction for the development of NGS,"
told Biodiscovery.
PacBio is a bit like Affymetrix at the time, and insisted on making progress in one direction as the stock hit rock bottom.
at that time Affymetrix was firmly into the clinical market to obtain an FDA registration, by clinical to bring new growth points, attracted TMO.
PacBio has been reducing error rates and miniaturizing machines.
" also lamented the deal, fearing monopoly issues, which have led to higher prices for PacBio sequencers and reagents.
Source: Biological Exploration.